Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Treating Prediabetes in the First Trimester

9 de outubro de 2018 atualizado por: Hilary Roeder, MD, University of California, San Diego

Treating Prediabetes in the First Trimester: A Randomized Controlled Trial

The investigators plan to study a sample of women with prediabetes (diagnosed by Hemoglobin A1c (HbA1c) 5.7-6.4% or fasting plasma glucose (FPG) 92-125 mg/dL) in the first trimester of pregnancy, and patients will be randomized to first trimester or third trimester treatment; the first trimester group will receive intervention immediately upon diagnosis of prediabetes whereas the third trimester group will receive only routine prenatal care until 28 weeks at which time they will receive intervention.

Intervention is defined as:

  • diabetes education
  • blood glucose monitoring
  • medications as needed
  • growth ultrasounds
  • antenatal testing

The primary outcome is umbilical cord C-Peptide >90th percentile. Secondary outcomes include neonatal fat mass at delivery, infant weight-for-length at 12 months of age, maternal gestational weight gain, and biomarkers (chemicals) measured in the placenta and the baby's umbilical cord blood.

The investigators hypothesize that women who undergo the above intervention in the first trimester will deliver significantly fewer neonates with umbilical cord C-Peptide >90th percentile, and that the neonates will have lower fat mass, and weight-for-length at 12 months. The investigators further hypothesize that a greater proportion of patients undergoing first trimester intervention will have appropriate maternal gestational weight gain as defined by the Institute of Medicine, and a greater proportion will return to prepregnancy weight within 12 months.

Visão geral do estudo

Status

Concluído

Intervenção / Tratamento

Descrição detalhada

The primary aim of the proposed research is to demonstrate that promoting a normoglycemic intrauterine milieu in women with prediabetes diagnosed in the first trimester of pregnancy with a Hemoglobin A1c (HbA1c) 5.7-6.4% or fasting plasma glucose (FPG) 92-125 mg/dL will decrease the accumulation of fetal white adipose tissue and development of infant/child obesity during the first year of life. This project is built upon the hypothesis that pregnant subjects with prediabetes randomized in the first trimester of pregnancy to strict glycemic control and pharmacotherapy as needed will have less fetal adiposity and adverse neonatal outcomes than those who receive the diagnosis of prediabetes but do not initiate care until the third trimester.

In the proposed study, 240 women meeting the above criteria for prediabetes at ≤ 15w0d gestation will be randomized to either first trimester or third trimester treatment. Each group will have diabetes education, initiate blood glucose monitoring, begin pharmacotherapy as needed (per established protocol), undergo growth ultrasounds, and antenatal testing. The first trimester arm will receive the above interventions immediately upon diagnosis of prediabetes whereas the third trimester arm will receive only routine prenatal care until 28 weeks at which time they will begin education and treatment. Both groups will be treated identically from 28 weeks until delivery.

In the 2013 the National Institutes of Health (NIH) Gestational Diabetes (GDM) Consensus Conference, the panel was concerned about adopting criteria that would increase prevalence of GDM (i.e. first trimester treatment) without first demonstrating improved outcomes. The results of this proposed trial, will allow us to fill key research gaps; this is the first prospective trial to evaluate the International Associations of Diabetes in Pregnancy Study Groups (IADPSG) recommendations for screening and diagnosing prediabetes in the first trimester.

Findings from this research will quantify the maternal and neonatal benefits and harms of treating women with prediabetes from early pregnancy. Additionally, the cohort of neonates that will result from this study can be followed into childhood to evaluate whether first trimester treatment has benefits beyond those anticipated at birth and may decrease the long-term incidence of obesity and diabetes.

Tipo de estudo

Intervencional

Inscrição (Real)

202

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • California
      • San Diego, California, Estados Unidos, 92103
        • UC San Diego Health System

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Pregnant women age 18 and above
  • Any ethnic background
  • English- or Spanish-speaking
  • Planned prenatal care/delivery at The University of California, San Diego's Hillcrest Hospital
  • Singleton pregnancy
  • Prediabetes diagnosed prior to 15w0d with HbA1c 5.7-6.4% or FPG 92-125 mg/dL

Exclusion Criteria:

  • Known Type 2 Diabetes (T2DM)
  • T2DM diagnosed with first trimester screening
  • Patients with known maternal/fetal indications for delivery <36w0d
  • Patients presenting for care after 15w0d

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: First Trimester Treatment of Prediabetes

Patients randomized to first trimester treatment will receive the following intervention immediately initiated upon diagnosis of prediabetes at <15 weeks 0 days gestation

  • diabetes education
  • blood glucose monitoring
  • medications as needed per California Diabetes and Pregnancy established protocol
  • growth ultrasounds
  • antenatal testing

Standardized treatment of prediabetes per California Diabetes and Pregnancy Program "Sweet Success"

  • diabetes education
  • blood glucose monitoring
  • medications as needed per California Diabetes and Pregnancy established protocol
  • growth ultrasounds
  • antenatal testing
Comparador Ativo: Third Trimester Treatment of Prediabetes

Patients randomized to third trimester treatment will receive the following intervention to be initiated at 28 weeks of gestation

  • diabetes education
  • blood glucose monitoring
  • medications as needed per California Diabetes and Pregnancy established protocol
  • growth ultrasounds
  • antenatal testing

Standardized treatment of prediabetes per California Diabetes and Pregnancy Program "Sweet Success"

  • diabetes education
  • blood glucose monitoring
  • medications as needed per California Diabetes and Pregnancy established protocol
  • growth ultrasounds
  • antenatal testing

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Prazo
Umbilical Cord C-Peptide >90th percentile
Prazo: 1 day (Collected at the time of delivery)
1 day (Collected at the time of delivery)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Neonatal fat mass
Prazo: Within 48 hours of delivery
Neonatal fat mass will be measured using an anthropometric model using weight, length, and flank skinfold thickness.
Within 48 hours of delivery
Adherence to the Institute of Medicine (IOM) guidelines for gestational weight gain
Prazo: Weight gain will be measured from immediately preconception until delivery
The IOM recommends that underweight women (BMI<18.5kg/m2) gain 28-40lbs, normal women (BMI 18.5-24.9 kg/m2) gain 25-35lbs, overweight women (BMI 25.0-29.9 kg/m2) gain 15-25lbs and obese women (BMI≥30 kg/m2) gain 11-20 lbs.
Weight gain will be measured from immediately preconception until delivery
Return to prepregnancy weight
Prazo: After 1 year post delivery
After 1 year post delivery

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
birthweight
Prazo: At delivery
At delivery
birthweight percentile
Prazo: At delivery
At delivery
Infant gender
Prazo: At delivery
At delivery
Ponderal index
Prazo: At delivery
Weight/length^3
At delivery
Neonatal Intensive Care Unit (NICU) Admission
Prazo: Within 10 days after birth
Within 10 days after birth
Infant weight-for-length
Prazo: 6 months and 12 months after delivery
6 months and 12 months after delivery
Need for pharmacotherapy to control hyperglycemia
Prazo: From 5 weeks gestation until time of delivery
From 5 weeks gestation until time of delivery
Birth trauma
Prazo: At delivery
Shoulder dystocia, brachial plexus injury
At delivery
Mode of delivery
Prazo: At delivery
Spontaneous delivery, operative vaginal delivery, cesarean delivery
At delivery
Indication for delivery
Prazo: At delivery
At delivery
Total gestational weight gain
Prazo: From immediately preconception until delivery
From immediately preconception until delivery
Postpartum weight retention
Prazo: Within 1 year of delivery
Within 1 year of delivery
Diagnosis of Preeclampsia
Prazo: From 20 weeks gestation until 6 weeks postpartum
From 20 weeks gestation until 6 weeks postpartum

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Hilary A Roeder, MD, UC San Diego Health System
  • Investigador principal: Gladys A Ramos, MD, UC San Diego Health System
  • Investigador principal: Thomas R Moore, MD, UC San Diego Health System

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de julho de 2013

Conclusão Primária (Real)

1 de junho de 2016

Conclusão do estudo (Real)

15 de junho de 2017

Datas de inscrição no estudo

Enviado pela primeira vez

15 de agosto de 2013

Enviado pela primeira vez que atendeu aos critérios de CQ

20 de agosto de 2013

Primeira postagem (Estimativa)

21 de agosto de 2013

Atualizações de registro de estudo

Última Atualização Postada (Real)

10 de outubro de 2018

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de outubro de 2018

Última verificação

1 de outubro de 2018

Mais Informações

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever